Bern, Switzerland, Thursday, January 26, 2023 - CIS Pharma attends the first Swiss RNA Therapeutics Summit in Bern. The Summit brings together stakeholders in the field of RNA Therapeutics from academia, biotechnology, pharma, manufacturing, government, and regulatory bodies to join forces in this rapidly advancing field. Christoph Schäfer, CEO, is looking forward to learn more from industry leaders about [...]

Bubendorf, Switzerland, Wednesday, January 18, 2023 -  CIS Pharma has identified its lead anti-B7H3 nanobody displaying promising affinity to the target. The production of the final candidate is up-scaled and the nanobody is labeled with radionuclides for a biodistribution study. These studies will be conducted within the project framework  funded by the Swiss Nanoscience Institute. CIS Pharma collaborates with [...]

Bubendorf, Switzerland, Tuesday, December 20, 2022 - CIS Pharma has successfully tested its anti-L1CAM radioligand against ovarian cancer in a Xenograft mouse model. The antibody-based radioligand comprises chelators conjugated to the antibody site-sepcifically. Labeled with Lutetium-177, the radioligand shows significant improvement of overall and progression-free survival, even at low doses. Christian Geraths, CSO of CIS Pharma says: «In a [...]

Bubendorf, Switzerland, Thursday, December 8, 2022 - CIS Pharma has successfully tested its linker technology. The technology creates immuno-conjugates with higher uniformity and stability compared to immuno-conjugates based on commonly used linkers. Quantitative functionalization of CIS Pharma’s monoclonal antibodies - applying site-directed conjugation - results in an ADC with high homogeneity and a DAR at nearly maximal value. A [...]

Bubendorf, Switzerland, Wednesday, November 23, 2022 - CIS Pharma has successfully tested its anti-L1CAM ADC technology against triple-negative breast cancer, TNBC, in a Zebrafish tumor model. An ADC carrying monomethyl auristatin E, MMAE, conjugated site-specifically to the antibody, demonstrated tumor size reduction greater than 50%. «The first efficacy study with our anti-L1CAM antibody and linker technology shows feasibility of [...]

Zurich, Switzerland, Tuesday, November 22, 2022 – CIS Pharma will attend the conference Clinical Operations in Oncology Trials Europe 2022. The conference offers insights and practical take-aways on successful collaboration with the clinical trials community. Christian Geraths, CSO and Christoph Schäfer, CEO, have planned a number of meetings to discuss clinical strategies to advance CIS Pharma’s immuno-conjugates to clinical [...]

Basel, Switzerland, Wednesday, November 2, 2022 – CIS Pharma will attend the Festival of Biologics, Europe’s most exciting biologic’s event, taking place in Basel. The team is looking forward to learn more from leading CDMOs, CROs, Biotech, Pharma and Academia about the latest trends in therapeutic use and manufacturing of biologics. Christian Geraths, CSO and Christoph Schäfer, CEO, Daniela [...]

Leipzig, Germany, Monday, October 24 - CIS Pharma will attend Bio- Europe, the gateway to the global biopharma community. The team is looking forward to an exciting programme including vital industry topics such as AI, pharmaceuticals, preventative medicine, big data and more. Also Christian Geraths, CSO and Christoph Schäfer, CEO have planned a number of meetings to foster partnerships [...]

Barcelona, Spain, Saturday, October 15, 2022 – CIS Pharma will attend the 35th Annual Congress of the European Association of Nuclear Medicine in Barcelona. The team is looking forward to learn more from world-leading physicians about the current clinical practice of radionuclide therapies and the perspectives and challenges of that specific cancer treatment modality. Christian Geraths, CSO and Christoph [...]

Bubendorf, Switzerland, Tuesday, October 4, 2022 – Based on the successful developments in the radioligand program, CIS Pharma and the ETH Zürich were granted continued funding for their development collaboration. Significant progress was achieved with respect to the lead optimization of CIS Pharma’s anti-L1CAM antibody as well as the polymer carrier platform. The ETH Zürich, specifically its radiopharmaceutical division Paul [...]

Basel, Switzerland, Wednesday, September 21, 2022 – CIS Pharma will attend the 22nd Annual Biotech in Europe Forum in Basel. Taking place during the Sachs Autumn Life Sciences Week, the team is looking forward to an exciting programme with speakers of the Biotech, Pharma and Financial industry. Christian Geraths, CSO and Christoph Schäfer, CEO have planned a number of [...]

Bubendorf, Switzerland, Tuesday, September 18 - CIS Pharma has initiated the production of an antibody-radionuclide conjugate, ARC, based on its humanized lead anti-CD171 antibody. The ARC Lutetium-177, at a radionuclide-to-antibody ratio, RAR, of four. Lutetium-177 is attached to the antibody by a site-directed coupling technology. The efficacy of the of the ARC well be evaluated in a Xenograft Mouse study [...]

Bubendorf, Switzerland, Wednesday, September 15, 2022 - CIS Pharma has initiated the production of an antibody-drug conjugate, ADC, based on its humanized lead anti-CD171 antibody. The ADC comprises monomethyl auristatin E, MMAE, at a drug-to-antibody ratio, DAR, of four. The toxins are attached to the antibody by a site-directed coupling technology. The efficacy of the ADCs will be evaluated in [...]

Villigen, Switzerland, Thursday, August 18, 2022 - CIS Pharma and its partner at ETH, Zürich, the division for radiopharmaceuticals, Paul Scherrer Institute, PSI, have made significant progress in their radionuclide anticancer treatment program. The lead candidate of the anti CD 171 platform shows high uptake in tumor tissue whereas background in non-targeted tissues is low as expected. The biodistribution [...]

Basel, Switzerland, Monday, May 2, 2022 - CIS Pharma will attend the Swiss Biotech Day in Basel, one of the leading biotechnology conferences in Europe. The team is looking forward to learn more about the global biotech industry in general and specifically about the status of the industry in Switzerland. Ignazio Cassis, the President of the Swiss Confederation, will address [...]

Bubendorf, Switzerland, Monday, March 14, 2022 - CIS Pharmas has identified two lead candidates for the development of the first nanobody polymer conjugate targeting B7H3, CD 276. Based on the results, upscale of nanobody production and optimization of the linker system is planned for the second half of 2022. In addition, proprietary monomers will be synthesized, serving as building [...]

Bubendorf, Switzerland, Friday, December 3, 2021 – CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. [...]

Bubendorf, Switzerland, Monday, November 22, 2021 – CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with the University of Applied Sciences in Basel. To widen the therapeutic use of oligonucleotides, CIS Pharma is developing technology for bio-conjugation of RNAi to targeting moieties, similar to the targeting [...]

Bubendorf, Switzerland, Monday, May 31, 2021 - CIS Pharma and the Paul Scherrer Institute of ETH were granted a two-year research program by Innosuisse to develop an antibody-radionuclide conjugate, ARC, at pre-clinical stage. The ARC is based on CIS Pharma’s polymer drug carriers to diagnose and treat L1CAM-positive forms of cancer. In addition, the research partners will investigate CIS Pharma’s [...]

Bubendorf, Switzerland, Thursday, May 20, 2021 - CIS Pharma has started the development of a nanobody against a novel tumor target. The antigen is homogeneously overexpressed in various forms of cancer, such as glioblastoma, lung or colorectal cancers and usually related to poor prognosis. The novel nanobody is developed to serve as a basis for CIS Pharma’s nanobody-polymer conjugates targeted [...]

Bubendorf, Switzerland, Friday, February 12, 2021 - CIS Pharma has initiated the development of a humanized monoclonal antibody against the target L1CAM / CD 171. L1CAM is a surface protein that is overexpressed in ovarian, colorectal, lung and other forms of cancer, with a fast progression of the disease, a high spread of metastases and therefore poor prognosis. The antibody [...]